AKT1 and type 2 diabetes mellitus: Both drugs affected signaling in the protein kinase B (AKT)/mammalian target of rapamycin pathway, which provides experimental evidence to support further investigation of metformin and rosiglitazone as first-line therapies for type 2 diabetes in cancer patients [87].